Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme.
about
The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS studyStatins in the treatment of chronic heart failure: a systematic reviewOngoing clinical trials of the pleiotropic effects of statinsRacial Differences in the Cholesterol-Lowering Effect of Statin.Effectiveness of statins in Medicare-eligible patients and patients < 65 years using clinical practice data.Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha study)Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia--Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)Statins: can the new generation make an impression?Rationale for combination therapy with statin drugs in the treatment of dyslipidemia.Rosuvastatin: a risk-benefit assessment for intensive lipid lowering.The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk.An update on the benefits and risks of rosuvastatin therapy.Rosuvastatin: achieving cholesterol targets.Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
P2860
Q24793837-3FADF56D-A948-4E18-8FE7-9455C4798176Q24814804-56C54FF0-34EE-4332-BCF7-141321A6F4A2Q28200294-BF4990A5-3928-4140-A167-A27306A8C0B1Q28219321-D0872F00-3C1D-4307-8B84-CA6780E8D2FAQ30244632-59A05223-2A37-43D0-A18C-6BCC537819EDQ31129888-8486130B-BBEE-47B9-9FB7-3829BF152A41Q33737675-9CA1BA62-5E2C-415A-AED1-B30EB68BDCA3Q35605494-48B58CE6-2416-4566-B4E7-0E51F44764C2Q35967383-53C6F54F-129C-4244-A81F-7B2C52AD04C5Q36025974-864652BA-ED09-49D4-B20F-1AD7FF4FE608Q36249934-D92D4D9A-0E6E-4E48-9D99-1344D8A6E5CDQ36752067-B771B8A8-B939-469B-A115-C3DB3C365213Q38200826-CA86EF44-545C-44B2-8D5D-B108CD1255FAQ40426760-088F8212-FA05-4B09-8E8E-21F6BA2BFD56Q46438003-55A0E274-1791-442B-A701-F0FFD5BCAAADQ46688401-2C85F74A-8F7A-418E-97FC-2D436B13F0AE
P2860
Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme.
@en
Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme.
@nl
type
label
Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme.
@en
Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme.
@nl
prefLabel
Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme.
@en
Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme.
@nl
P2860
P1476
Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme.
@en
P2093
Herbert Schuster
Jonathan C Fox
P2860
P304
P356
10.1517/14656566.5.5.1187
P407
P577
2004-05-01T00:00:00Z